H. Lundbeck A/S

Ottiliavej 9   Tel +45 36 30 13 11   E-mail investor@lundbeck.com
DK-2500 Valby København   Fax +45 36 43 82 62   www.lundbeck.com

Release No 256

22 January 2007

Change in Lundbeck A/S Executive Management

Executive Vice President, CFO Hans Henrik Munch-Jensen has decided to retire from his position in connection with the presentation of the company's annual report 2006 on the 7th of March 2007. Recruitment of a new Executive Vice President and CFO has been initiated.

Furthermore, Lundbeck's marketing and sales activities will be concentrated under one member of Executive Management. As a consequence, Ole Chrintz will withdraw from Lundbeck Executive Management, but will continue his current responsibilities within the company, including responsibility for establishing a Lundbeck sales organization in the US.

CEO Claus Braestrup, Executive Vice President Lars Bang, Supply Operations, Engineering & IT, and Executive Vice President Stig Løkke Pedersen, Commercial Operations, will hereafter constitute Lundbeck's Executive Management.

The content of this release does not change the Lundbeck Group's previously announced expectations as announced in connection with reporting for the 3rd quarter 2006 financial result.

Lundbeck contacts

Steen Juul Jensen
Vice President
+45 36 43 30 06

Investors: *Media:*

Mads Bjerregaard Pedersen   Caroline Broge
Investor Relations Officer   Media Relations Manager
+45 36 43 41 04   +45 36 43 26 38

Jacob Tolstrup
Investor Relations Manager,
North America
+1 201 350 0187

_____

Stock exchange release No 256 – 22 January 2007

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2005, the company's revenue was DKK 9.1 billion (approximately EUR 1.2 billion or USD 1.5 billion). The number of employees is approximately 5,000 globally. For further information, please visit www.lundbeck.com